close
Fox News Flash top headlines are here. Check out what’s clicking on Foxnews.com.
A Japanese health ministry panel on Monday recommended approval of the Alzheimer’s disease treatment Leqembi, following standard approval for the drug granted by U.S. regulators last month.
REVANCE’S BOTOX RIVAL GETS FDA APPROVAL FOR PAINFUL NECK MUSCLE CONDITION
The expert panel’s decision sets the stage for official approval of the drug, co-developed by Japan’s Eisai and U.S.-based Biogen.
Dr. Seth Gale points out evidence of Alzheimer’s disease on PET scans at the Center for Alzheimer Research and Treatment (CART) at Brigham and Women’s Hospital in Boston, Massachusetts, on March 30, 2023. (REUTERS/Brian Snyder/File Photo)
An Eisai executive said this month the company expects to begin marketing Leqembi in Japan within about 60 days of receiving insurance reimbursement approval from the country’s national health system.
CLICK HERE TO GET THE FOX NEWS APP
Things like your name, home address, date of birth and even your Social Security number…
Most people never think about Android security updates until a headline like this appears. Suddenly,…
The next time you pull up to the drive-thru at Burger King, you may notice…
You may think you can spot a crypto scam from a mile away. But what…
The first Tesla Cybercab has officially rolled off the floor at Tesla Gigafactory Texas. And…
Smart glasses promise a future where technology blends into everyday life. You can ask a…